This article examines the global accessibility challenges of Lenacapavir, a groundbreaking HIV prevention drug that demonstrated extraordinary efficacy in clinical trials. It contrasts two perspectives: Gilead Sciences claims rapid progress in making the drug available through voluntary licensing agreements with six generic manufacturers for 120 countries, while critics led by Dr. Andrew Hill argue these agreements exclude crucial middle-income countries representing 23% of global HIV infections. The controversy centers on pricing and accessibility, with Hill calculating generic production could cost $40-95 annually per patient versus Gilead's $40,000 treatment price in high-income markets. Critics suggest compulsory licensing may be necessary if Gilead doesn't modify its approach, citing Colombia's 2024 precedent with dolutegravir. The article notes political shifts threaten HIV funding programs, potentially impacting global distribution efforts. Read More

Explore the global collaboration landscape for Kv1.3-targeting drugs in 2024, highlighting key clinical players, regional licensing preferences, and strategic partner selection. Learn how to identify ideal license-out opportunities and leverage Unibest's international BD expertise to maximize your drug pipeline's value. Read More

Patent Cliff Looms – Can Kv1.3 Take the Baton for the Next Wave of Drug Licensing?1. Introduction: The Patent Cliff Is Coming, Leaving Market Voids“Patent cliff” refers to the sharp revenue drop pharma companies face when blockbuster drug patents expire, opening the door to generic competition. Read More

This week, there are 4 drugs in the patent and exclusivity list. They are: - GILEAD SCIENCES INC's LIVDELZI, containing active ingredient SELADELPAR LYSINE - ABBVIE INC's KYBELLA, containing active ingredient DEOXYCHOLIC ACID - GENENTECH INC's COTELLIC, containing active ingredient COBIMETINIB FUMARATE - ARCUTIS BIOTHERAPEUTICS INC's ZORYVE, containing active ingredient ROFLUMILAST Read More

Explore the future beyond GLP-1 drugs in diabetes and obesity treatment with amylin analogs. This article dives into the clinical promise, market opportunities, key challenges, and licensing strategies for amylin-based therapies, highlighting why they may redefine the next wave of metabolic medicine. Learn how Unibest supports pharma companies in licensing and accelerating amylin drug development. Read More

This week, there are 12 drugs in the patent and exclusivity list. They are: - NEURELIS INC's VALTOCO, containing active ingredient DIAZEPAM - DUCHESNAY INC's OSPHENA, containing active ingredient OSPEMIFENE - GILEAD SCIENCES INC's ZYDELIG, containing active ingredient IDELALISIB - SUN PHARMACEUTICAL INDUSTRIES LTD's WINLEVI, containing active ingredient CLASCOTERONE - SENTYNL THERAPEUTICS INC's ZOKINVY, containing active ingredient LONAFARNIB - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's TRELEGY ELLIPTA, containing active ingredient FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's ANORO ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE's INCRUSE ELLIPTA, containing active ingredient UMECLIDINIUM BROMIDE - GILEAD SCIENCES INC's VEKLURY, containing active ingredient REMDESIVIR Read More

This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVARTIS PHARMACEUTICALS CORP's ENTRESTO, containing active ingredient SACUBITRIL; VALSARTAN - BIOCODEX SA's DIACOMIT, containing active ingredient STIRIPENTOL - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - SERVIER PHARMACEUTICALS LLC's TIBSOVO, containing active ingredient IVOSIDENIB - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's KRINTAFEL, containing active ingredient TAFENOQUINE SUCCINATE Read More

This article explores the growing preference for small molecule GLP-1 receptor agonists in developing countries, driven by cost sensitivity, infrastructure limitations, and the need for scalable oral therapies for diabetes and obesity. It examines the economic and clinical advantages of small molecules over biologics, analyzes emerging market dynamics, and outlines how Unibest leverages its sourcing, regulatory, and export expertise to support global access. The piece also reviews current pipeline innovations and the future potential of affordable GLP-1 drugs in underserved regions. Read More

This week, there are 13 drugs in the patent and exclusivity list. They are: - GILEAD SCIENCES INC's BIKTARVY, containing active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's ODEFSEY, containing active ingredient EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's VEMLIDY, containing active ingredient TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's GENVOYA, containing active ingredient COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GILEAD SCIENCES INC's DESCOVY, containing active ingredient EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - FRESENIUS KABI USA LLC's OMEGAVEN, containing active ingredient FISH OIL TRIGLYCERIDES - ANI PHARMACEUTICALS INC's VEREGEN, containing active ingredient SINECATECHINS - NOVARTIS PHARMACEUTICALS CORP's PROMACTA KIT, containing active ingredient ELTROMBOPAG OLAMINE Read More